14 g vs. 16 g in Breast Biopsy
Comparison of Needle Gauge 14 vs. Gauge 16 in Breast Biopsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tübingen, Germany, 72076
- Department of Women's Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Minimum age of 18 years
- Informed consent available
- Palpable and non-palpable breast findings
- Tumor size 5-20 mm
- Findings of sonographic BI-RADS® classification 2-5.
- Guideline-oriented indication for bioptic clarification
Exclusion Criteria:
- No reliable sonographic demarcation of the finding
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 14 gauge needle biopsy
breast biopsy will be performed with 14 gauge needle
|
breast biopsy using different needle gauges
|
|
Active Comparator: 16 gauge needle biopsy
breast biopsy will be performed with 16 gauge needle
|
breast biopsy using different needle gauges
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic accuracy
Time Frame: 1 year
|
|
1 year
|
|
Diagnostic quality
Time Frame: 1 year
|
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain related to the biopsy procedure
Time Frame: 1 year
|
Subjective pain perception measured visual analog scale
|
1 year
|
|
Duration time of the biopsy procedure
Time Frame: 1 year
|
Duration time of the biopsy procedure
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Gauge 14/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Biopsy
-
NCT03842358Completed
-
NCT04398537Completed
-
NCT07154446Not yet recruiting
-
NCT01811043CompletedImaging Guided Breast Biopsy
-
NCT02085239WithdrawnPain Management After Breast Biopsy
-
NCT06371989Completed
-
NCT07338721RecruitingBreast Carcinoma | Sentinel Lymph Node Biopsy
-
NCT07219277RecruitingBreast Cancer, Liquid Biopsy, Early Detection
-
NCT05623241RecruitingBreast Cancer | Liquid Biopsy
Clinical Trials on needle biopsy
-
NCT01566045Withdrawn
-
NCT06541470CompletedDiagnosis | Biopsy | Pleura; Exudate
-
NCT03789851Unknown
-
NCT04500262Recruiting
-
NCT01598194CompletedMalignant Neoplasm of Pancreas | Solid Pancreatic Mass Lesions
-
NCT01727921CompletedPancreatic Neoplasms